WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock

$17.59-1.04 (-5.58%)
Updated Mar 28, 2024
ELVN Price
$17.59
Fair Value Price
$2.81
Market Cap
$727.30M
52 Week Low
$9.80
52 Week High
$23.98
P/E
-8.75x
P/B
2.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$71.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$61M
Beta
0.59
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ELVN Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ELVN ($17.59) is overvalued by 526.13% relative to our estimate of its Fair Value price of $2.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELVN ($17.59) is not significantly undervalued (526.13%) relative to our estimate of its Fair Value price of $2.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELVN due diligence checks available for Premium users.

Be the first to know about important ELVN news, forecast changes, insider trades & much more!

Valuation

ELVN fair value

Fair Value of ELVN stock based on Discounted Cash Flow (DCF)
Price
$17.59
Fair Value
$2.81
Overvalued by
526.13%
ELVN ($17.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELVN ($17.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ELVN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.75x
Industry
14.26x
Market
44.51x

ELVN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.96x
Industry
6.21x
ELVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ELVN's financial health

Profit margin

Revenue
$0.0
Net Income
-$19.4M
Profit Margin
0%
ELVN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$271.9M
Liabilities
$26.0M
Debt to equity
0.11
ELVN's short-term assets ($266.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELVN's short-term assets ($266.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.5M
Investing
$38.7M
Financing
$90.0k
ELVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ELVN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ELVN$727.30M-5.58%-8.75x2.96x
FATE$728.40M0.00%-4.48x1.98x
AUPH$724.53M+0.20%-9.28x1.92x
KRRO$721.98M+1.66%-1.70x4.25x
ALT$721.71M+14.51%-6.13x3.72x

Enliven Therapeutics Stock FAQ

What is Enliven Therapeutics's quote symbol?

(NASDAQ: ELVN) Enliven Therapeutics trades on the NASDAQ under the ticker symbol ELVN. Enliven Therapeutics stock quotes can also be displayed as NASDAQ: ELVN.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.

What is the 52 week high and low for Enliven Therapeutics (NASDAQ: ELVN)?

(NASDAQ: ELVN) Enliven Therapeutics's 52-week high was $23.98, and its 52-week low was $9.80. It is currently -26.65% from its 52-week high and 79.49% from its 52-week low.

How much is Enliven Therapeutics stock worth today?

(NASDAQ: ELVN) Enliven Therapeutics currently has 41,347,632 outstanding shares. With Enliven Therapeutics stock trading at $17.59 per share, the total value of Enliven Therapeutics stock (market capitalization) is $727.30M.

Enliven Therapeutics stock was originally listed at a price of $60.00 in Mar 12, 2020. If you had invested in Enliven Therapeutics stock at $60.00, your return over the last 4 years would have been -70.68%, for an annualized return of -26.42% (not including any dividends or dividend reinvestments).

How much is Enliven Therapeutics's stock price per share?

(NASDAQ: ELVN) Enliven Therapeutics stock price per share is $17.59 today (as of Mar 28, 2024).

What is Enliven Therapeutics's Market Cap?

(NASDAQ: ELVN) Enliven Therapeutics's market cap is $727.30M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Enliven Therapeutics's market cap is calculated by multiplying ELVN's current stock price of $17.59 by ELVN's total outstanding shares of 41,347,632.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.